Jubilant Biosys announces merger with Jubilant Chemsys

Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Life Sciences Limited, announced completion of the merger with its sister company Jubilant Chemsys Limited, based in Noida, India. The combined entities will now operate as Jubilant Biosys Limited.

The merger will simplify operations and provide customers with a single brand access for a wide range of discovery, IND and PR&D and GMP development services. Biosys had earlier announced significant investment in building new state-of-the-art research facilities in Greater Noida and in Bengaluru, India to cater to increasing customer demand for its functional services (medicinal & synthetic chemistry, structural biology, DMPK, Biology & GMP scale-up) and notably integrated drug discovery services.

Commenting on the merger, Marcel Velterop, President- Jubilant Biosys Limited and CDMO, said, “We are delighted to make this merger happen and focus our investments for growth to expand both the chemistry as well as integrated drug discovery capabilities. It provides clarity to customers and enables us to better deliver on our “4D” promise of accelerating the discovery process through increased digitization of our operations and information flow.”

Jubilant Biosys, a Bengaluru based wholly owned subsidiary of Jubilant Life Sciences Ltd, offers contract research & development services for global pharmaceutical innovators. Biosys has a proven track record of delivering over 75 integrated programs in multiple therapeutic areas. Its sister company, TrialStat Solution Inc., provides an advanced EDC platform to accelerate clinical trials’ data capture and processing.

Website | + posts

HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.

What's your take on this post ? Comment: